Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

The Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Melanoma

Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma

Metastatic Melanoma Therapies OPDIVO® (nivolumab) + YERVOY® (ipilimumab)

Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis - ScienceDirect

Half of the patients with metastatic melanoma treated with nivolumab- ipilimumab are still alive after 5 years - BJMO

Nivolumab in Combination With Ipilimumab in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma - The ASCO Post

Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma - Southern Iowa Mental Health Center